肺がんゲノム検査薬市場- 世界の産業規模、動向、機会、予測、技術別、サンプルタイプ別、パネルタイプ別、エンドユーザー別、地域別競合別、2019～2029年

肺がんゲノム検査薬の世界市場は、2023年に18億米ドルと評価され、2029年までの予測期間のCAGRは5.25%で着実な成長が予測されています。

肺がんは、世界で最も罹患率が高く、致命的ながんのひとつです。肺がんは様々な遺伝的・分子的プロファイルを持つ複雑な疾患であり、患者の予後を改善するためには正確な診断と治療が不可欠です。ゲノム検査は、分子プロファイリングまたは遺伝子検査としても知られ、がん患者のDNAとRNAを分析して腫瘍細胞内の特定の遺伝子変異や変化を同定する方法です。このアプローチは、がんの遺伝子構成に関する貴重な洞察を提供し、腫瘍医が治療戦略についてより多くの情報に基づいた決定を下すのに役立ちます。肺がんの場合、疾患の不均一性からゲノム検査はますます重要になってきています。肺がんは非小細胞肺がん（NSCLC）と小細胞肺がん（SCLC）の2つに大別されます。これらの分類の中にも多数の亜型があり、それぞれが明確な遺伝子マーカーを持っています。ゲノム検査はこれらのマーカーを同定することを可能にし、より個別化された効果的な治療アプローチを可能にします。

肺がんは、高い罹患率とともに世界の健康問題であり続けています。ゲノム検査は、肺がんに存在する遺伝子変化に特異的に対処する標的治療の開発につながった。肺がんにおける免疫療法の市場は急速に拡大しています。ゲノム検査は、免疫療法が有効である可能性の高い患者を同定することができ、治療法選択のための重要なツールとなっています。ゲノム検査の非侵襲的方法であるリキッドバイオプシーは人気を集めています。リキッドバイオプシーは非侵襲的なゲノム検査法であり、患者の血液中の循環腫瘍DNAを分析することで、病気の進行や治療反応に関する情報をリアルタイムで得ることができます。

市場の促進要因

肺がん罹患率の上昇が肺がんゲノム検査薬の世界市場を牽引

医療支出の増加が肺がんゲノム検査薬の世界市場を牽引

主要市場課題

限られた認知度とアクセシビリティ

コスト制約

データプライバシーとセキュリティ

標準化と規制

進化するゲノム情勢

変化への抵抗

倫理的ジレンマ

主要市場動向

技術の進歩

セグメント別洞察

技術別洞察

サンプルタイプ別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 肺がんゲノム検査薬の世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 技術別（ポリメラーゼ連鎖反応、次世代シーケンサー、蛍光in-situハイブリダイゼーション、その他）
  • サンプルタイプ別（組織生検、リキッドバイオプシー）
  • パネルタイプ別（マルチジーンパネル、シングルジーンパネル）
  • エンドユーザー別（研究機関、病院クリニック、診断ラボ、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 技術別
  • サンプルタイプ別
  • パネルタイプ別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋の肺がんゲノム検査薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 技術別
  • サンプルタイプ別
  • パネルタイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の肺がんゲノム検査薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 技術別
  • サンプルタイプ別
  • パネルタイプ別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の肺がんゲノム検査薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 技術別
  • サンプルタイプ別
  • パネルタイプ別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の肺がんゲノム検査薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 技術別
  • サンプルタイプ別
  • パネルタイプ別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの肺がんゲノム検査薬市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 技術別
  • サンプルタイプ別
  • パネルタイプ別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と新興国市場開拓

• 製品発表
• 合併・買収

第12章 肺がんゲノム検査薬の世界市場のSWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

第15章 戦略的提言

第16章 戦略的提言当社について免責事項

Global Lung Cancer Genomic Testing Medicine Market was valued at USD 1.80 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Lung cancer is one of the most prevalent and deadly cancers worldwide. It is a complex disease that can have various genetic and molecular profiles, making precise diagnosis and treatment crucial for better patient outcomes. In recent years, the field of oncology has witnessed significant progress in the form of genomic testing.Genomic testing, also known as molecular profiling or genetic testing, is a method that analyzes the DNA and RNA of a cancer patient to identify specific genetic mutations or alterations in the tumor cells. This approach provides valuable insights into the genetic makeup of the cancer and helps oncologists make more informed decisions about treatment strategies. In the context of lung cancer, genomic testing has become increasingly important due to the heterogeneity of the disease. Lung cancer can be broadly categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Within these categories, there are numerous subtypes, each with its distinct genetic markers. Genomic testing enables the identification of these markers, allowing for a more personalized and effective treatment approach.

Lung cancer continues to be a global health concern, with a high incidence rate. This has created a substantial demand for more precise diagnostic and treatment options.Genomic testing has led to the development of targeted therapies that specifically address the genetic alterations present in an individual's lung cancer. These therapies are often more effective and have fewer side effects compared to traditional chemotherapy.The market for immunotherapies in lung cancer is expanding rapidly. Genomic testing can identify patients who are more likely to benefit from immunotherapy, making it a critical tool for treatment selection.Liquid biopsies, a non-invasive method of genomic testing, are gaining traction. They allow for the analysis of circulating tumor DNA in the patient's blood, providing real-time information about the disease's progression and treatment response.

Key Market Drivers

Rising Incidence of Lung Cancer is Driving the Global Lung Cancer Genomic Testing Medicine Market

Lung cancer is one of the most common and deadliest forms of cancer worldwide, accounting for a substantial number of cancer-related deaths each year. The alarming rise in the incidence of lung cancer has prompted a significant shift in the way this disease is diagnosed and treated. Genomic testing, which involves analyzing the genetic makeup of lung cancer cells, has emerged as a powerful tool in the fight against this devastating disease. As the incidence of lung cancer continues to grow, the global lung cancer genomic testing medicine market is witnessing unprecedented growth.Lung cancer remains a global health concern, and its incidence has been steadily increasing in recent years.

Smoking remains the leading cause of lung cancer, and despite significant efforts to reduce tobacco use, millions of people worldwide continue to smoke. This addictive habit continues to be a primary driver of lung cancer cases.Exposure to environmental carcinogens, such as radon gas, asbestos, and air pollution, has also been linked to an increased risk of lung cancer. As industrialization and urbanization progress, more people are exposed to these risk factors.Sedentary lifestyles, unhealthy diets, and increasing stress levels can contribute to the development of various health issues, including lung cancer. These lifestyle factors are becoming increasingly prevalent, especially in urban areas. Lung cancer is more common in older individuals, and as the global population ages, the number of lung cancer cases is expected to rise. In some regions, gender disparities exist, with lung cancer being more prevalent in men than in women. However, the incidence of lung cancer in women is also on the rise.

Increased Healthcare Spending is Driving the Global Lung Cancer Genomic Testing Medicine Market

One of the primary drivers behind the growth of the global lung cancer genomic testing medicine market is the substantial increase in healthcare spending worldwide. Governments, insurance companies, and private healthcare providers are investing heavily in the development and implementation of genomic testing for lung cancer patients.Greater funding and investment in healthcare infrastructure enable more hospitals and clinics to acquire advanced genomic testing technologies. This, in turn, allows a broader range of lung cancer patients to access these cutting-edge diagnostic and treatment options. Increased financial support from both public and private sectors fosters research and development in the field of genomic testing for lung cancer. This investment accelerates the discovery of new biomarkers and the development of targeted therapies, enhancing the effectiveness of treatment.With more healthcare spending dedicated to patient education and awareness campaigns, individuals are becoming increasingly informed about the benefits of genomic testing. As a result, they are more likely to request and participate in these tests, thus driving market growth.Many healthcare systems are expanding insurance coverage to include genomic testing for lung cancer. This ensures that a wider range of patients can afford these tests, further promoting their adoption.

The impact of increased healthcare spending on the global lung cancer genomic testing medicine market is significant. As more countries invest in research, technology, and healthcare infrastructure, the market is experiencing rapid growth. It is not only the developed nations that are driving this market but also emerging economies that are recognizing the importance of precision medicine in their healthcare systems. Moreover, collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions have intensified due to the heightened focus on lung cancer genomic testing. This collective effort is facilitating the development of innovative solutions and the commercialization of new products, leading to further market expansion.

Key Market Challenges

Limited Awareness and Accessibility

One of the foremost challenges in the lung cancer genomic testing market is the limited awareness among patients, healthcare providers, and even governments. Many people are unaware of the existence and importance of these tests, resulting in underutilization. Furthermore, access to genomic testing varies significantly across different regions, and not all patients have the opportunity to benefit from this advanced technology. Ensuring that patients and physicians are well-informed and expanding access to testing is crucial for market growth.

Cost Constraints

The cost of genomic testing can be a significant barrier for many patients and healthcare systems. High costs associated with test development, equipment, and analysis often translate to expensive tests, limiting their availability and affordability. To address this challenge, there is a need for ongoing research to reduce testing costs and for healthcare systems to consider reimbursing patients for these tests to make them more accessible.

Data Privacy and Security

Genomic testing generates a vast amount of sensitive patient data, including genetic information that has the potential for misuse if not adequately protected. Privacy concerns and data security challenges are a significant hurdle in the adoption of genomic testing. The industry needs to establish robust data protection protocols and regulatory frameworks to address these concerns and ensure patient trust.

Standardization and Regulation

The lung cancer genomic testing medicine market lacks standardized protocols for testing, reporting, and interpretation of results. This inconsistency can lead to discrepancies in the quality of testing and results, affecting patient care. Establishing comprehensive regulations and guidelines is essential to ensure the accuracy and reliability of genomic testing across the globe.

Evolving Genomic Landscape

The field of genomics is continually evolving, with new discoveries and technologies emerging at a rapid pace. This presents both an opportunity and a challenge for the lung cancer genomic testing market. Keeping up with the latest advancements in genomics and integrating them into clinical practice is vital, but it also requires ongoing investments in research, development, and training.

Resistance to Change

Changing traditional healthcare practices and introducing genomic testing into clinical workflows can be met with resistance from both healthcare providers and patients. There may be skepticism and reluctance to embrace new technologies and shift away from conventional treatment approaches. Effective educational and advocacy efforts are necessary to overcome this challenge.

Ethical Dilemmas

Genomic testing in lung cancer raises ethical questions regarding data use, informed consent, and potential discrimination based on genetic information. These ethical dilemmas must be addressed through transparent policies and guidelines to ensure that patients' rights and well-being are protected.

Key Market Trends

Technological Advancements

The global healthcare industry is experiencing a profound transformation, driven by technological advancements that are changing the way diseases are diagnosed, treated, and managed. In the realm of cancer care, one area where these innovations are making a significant impact is in the field of genomic testing for lung cancer. Lung cancer is a major global health concern, and as the second most common cancer, early detection and personalized treatment are essential for improving patient outcomes. The rise of genomic testing has opened new horizons in the battle against lung cancer, and it is propelling the global Lung Cancer Genomic Testing Medicine Market to new heights.

Next-Generation Sequencing (NGS) technologies have revolutionized genomic testing, enabling the comprehensive analysis of a patient's DNA. This has led to a deeper understanding of the genetic mutations responsible for lung cancer, allowing for more precise and personalized treatment plans.Liquid biopsies, which involve the analysis of blood samples, have gained traction as a non-invasive method for detecting lung cancer-related mutations. These tests are less invasive and can be performed more frequently, allowing for better monitoring of treatment response.Artificial Intelligence (AI) and machine learning are being used to analyse vast amounts of genomic data rapidly and accurately, assisting healthcare providers in identifying potential treatment options and predicting patient outcomes.As genomic testing identifies specific mutations, pharmaceutical companies are developing targeted therapies that can precisely attack these cancer-causing alterations. This approach minimizes side effects and maximizes the effectiveness of treatments.

Segmental Insights

Technology Insights

Basedon the category of Technology, Polymerase Chain Reaction emerged as the dominant player in the global market for Lung Cancer Genomic Testing Medicine in 2023.Polymerase Chain Reaction, or PCR, is a critical technology in the field of molecular biology and genomics. It allows for the amplification of specific DNA sequences, making it easier to detect mutations and alterations in the DNA of lung cancer cells. PCR has become a cornerstone in lung cancer genomic testing due to its precision, speed, and cost-effectiveness.PCR can detect even tiny amounts of DNA, making it highly sensitive and specific in identifying genetic mutations in lung cancer. This precision is crucial in determining the most suitable treatment options for each patient.

PCR is a rapid technique that can generate results in a matter of hours, allowing healthcare providers to make timely decisions about patient care. This speed is especially important in the fast-paced world of cancer treatment.PCR is a cost-effective method compared to other genomic testing technologies. This affordability ensures that more patients can access and benefit from genomic testing, contributing to better treatment outcomes.The information derived from PCR can guide oncologists in tailoring treatments to a patient's specific genetic profile. This personalized approach often results in better treatment responses and fewer side effects.PCR is not only useful in the initial diagnosis but also in monitoring disease progression and response to treatment. By regularly testing for genetic changes, clinicians can adapt treatment strategies as needed.

Sample type Insights

The Tissue Biopsy segment is projected to experience rapid growth during the forecast period. Tissue biopsy, which involves extracting a small sample of lung tissue for analysis, has emerged as the primary method for conducting genomic testing in lung cancer cases. Tissue biopsy provides a comprehensive view of the genetic mutations and alterations present in a patient's tumor. This comprehensive analysis enables oncologists to make more accurate and personalized treatment decisions. Tissue biopsy is known for its accuracy and reliability in identifying genomic alterations. It is considered the gold standard for detecting specific mutations and guiding treatment choices. Lung cancer is a highly heterogeneous disease, with genetic changes occurring at different sites within the tumor. Tissue biopsy allows for the assessment of this intra-tumor heterogeneity, providing a more accurate representation of the genetic landscape of the cancer. Genomic testing from tissue biopsy can identify predictive biomarkers, such as EGFR mutations or ALK rearrangements, which can guide the selection of targeted therapies. This approach leads to more successful treatment outcomes and fewer adverse effects.

Regional Insights

North America emerged as the dominant region in the global Lung Cancer Genomic Testing Medicine market in 2023, holding the largest market share in terms of value. North America, particularly the United States and Canada, has been at the forefront of lung cancer genomic testing medicine research and innovation. World-class research institutions, medical centers, and pharmaceutical companies in the region have invested heavily in the development of cutting-edge technologies and therapies. This has contributed to North America's leadership in the field. The region boasts a significant presence of advanced technology companies and genomic sequencing centers that offer state-of-the-art equipment and expertise in genomic testing. This accessibility to cutting-edge technology has allowed North American healthcare providers to offer comprehensive genomic testing services to lung cancer patients.

Key Market Players

QIAGEN NV

Agilent Technologies Inc.

Thermo Fisher Scientific Inc.

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

CENTOGENE N.V.

BGI Genomics Co. Ltd.

CeGaT GmbH

Illumina Inc.

F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Medicine Market,By Technology:

• Polymerase Chain Reaction
• Next-Generation Sequencing
• Fluorescence In-Situ Hybridization
• Others

Lung Cancer Genomic Testing Medicine Market,By Sample Type:

• Tissue Biopsy
• Liquid Biopsy

Lung Cancer Genomic Testing Medicine Market,By Panel Type:

• Multi-Gene Panel
• Single-Gene Panel

Lung Cancer Genomic Testing Medicine Market,By End-User:

• Research Organization
• Hospitals Clinics
• Diagnostic Laboratories
• Others

Lung Cancer Genomic Testing Medicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Lung Cancer Genomic Testing Medicine Market Outlook

• 4.1.Market Size Forecast
  • 4.1.1.By Value
• 4.2.Market Share Forecast
  • 4.2.1.By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and Others)
  • 4.2.2.By Sample Type (Tissue Biopsy and Liquid Biopsy)
  • 4.2.3.By Panel Type (Multi-Gene Panel and Single-Gene Panel)
  • 4.2.4.By End-User (Research Organization, Hospitals Clinics, Diagnostic Laboratories, Others)
  • 4.2.5.By Region
  • 4.2.6.By Company (2023)
• 4.3.Market Map
  • 4.3.1.By Technology
  • 4.3.2.By Sample Type
  • 4.3.3.By Panel Type
  • 4.3.4.By End-User
  • 4.3.5.By Region

5.Asia Pacific Lung Cancer Genomic Testing Medicine Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Technology
  • 5.2.2.By Sample Type
  • 5.2.3.By Panel Type
  • 5.2.4.By End-User
  • 5.2.5.By Country
• 5.3.Asia Pacific: Country Analysis
  • 5.3.1.China Lung Cancer Genomic Testing Medicine Market Outlook
    • 5.3.1.1.Market Size Forecast
      • 5.3.1.1.1.By Value
    • 5.3.1.2.Market Share Forecast
      • 5.3.1.2.1.By Technology
      • 5.3.1.2.2.By Sample Type
      • 5.3.1.2.3.By Panel Type
      • 5.3.1.2.4.By End-User
  • 5.3.2.India Lung Cancer Genomic Testing Medicine Market Outlook
    • 5.3.2.1.Market Size Forecast
      • 5.3.2.1.1.By Value
    • 5.3.2.2.Market Share Forecast
      • 5.3.2.2.1.By Technology
      • 5.3.2.2.2.By Sample Type
      • 5.3.2.2.3.By Panel Type
      • 5.3.2.2.4.By End-User
  • 5.3.3.Australia Lung Cancer Genomic Testing Medicine Market Outlook
    • 5.3.3.1.Market Size Forecast
      • 5.3.3.1.1.By Value
    • 5.3.3.2.Market Share Forecast
      • 5.3.3.2.1.By Technology
      • 5.3.3.2.2.By Sample Type
      • 5.3.3.2.3.By Panel Type
      • 5.3.3.2.4.By End-User
  • 5.3.4.Japan Lung Cancer Genomic Testing Medicine Market Outlook
    • 5.3.4.1.Market Size Forecast
      • 5.3.4.1.1.By Value
    • 5.3.4.2.Market Share Forecast
      • 5.3.4.2.1.By Technology
      • 5.3.4.2.2.By Sample Type
      • 5.3.4.2.3.By Panel Type
      • 5.3.4.2.4.By End-User
  • 5.3.5.South Korea Lung Cancer Genomic Testing Medicine Market Outlook
    • 5.3.5.1.Market Size Forecast
      • 5.3.5.1.1.By Value
    • 5.3.5.2.Market Share Forecast
      • 5.3.5.2.1.By Technology
      • 5.3.5.2.2.By Sample Type
      • 5.3.5.2.3.By Panel Type
      • 5.3.5.2.4.By End-User

6.Europe Lung Cancer Genomic Testing Medicine Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Technology
  • 6.2.2.By Sample Type
  • 6.2.3.By Panel Type
  • 6.2.4.By End-User
  • 6.2.5.By Country
• 6.3.Europe: Country Analysis
  • 6.3.1.France Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Technology
      • 6.3.1.2.2.By Sample Type
      • 6.3.1.2.3.By Panel Type
      • 6.3.1.2.4.By End-User
  • 6.3.2.Germany Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Technology
      • 6.3.2.2.2.By Sample Type
      • 6.3.2.2.3.By Panel Type
      • 6.3.2.2.4.By End-User
  • 6.3.3.Spain Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Technology
      • 6.3.3.2.2.By Sample Type
      • 6.3.3.2.3.By Panel Type
      • 6.3.3.2.4.By End-User
  • 6.3.4.Italy Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Technology
      • 6.3.4.2.2.By Sample Type
      • 6.3.4.2.3.By Panel Type
      • 6.3.4.2.4.By End-User
  • 6.3.5.United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Technology
      • 6.3.5.2.2.By Sample Type
      • 6.3.5.2.3.By Panel Type
      • 6.3.5.2.4.By End-User

7.North America Lung Cancer Genomic Testing Medicine Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Technology
  • 7.2.2.By Sample Type
  • 7.2.3.By Panel Type
  • 7.2.4.By End-User
  • 7.2.5.By Country
• 7.3.North America: Country Analysis
  • 7.3.1.United States Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Technology
      • 7.3.1.2.2.By Sample Type
      • 7.3.1.2.3.By Panel Type
      • 7.3.1.2.4.By End-User
  • 7.3.2.Mexico Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Technology
      • 7.3.2.2.2.By Sample Type
      • 7.3.2.2.3.By Panel Type
      • 7.3.2.2.4.By End-User
  • 7.3.3.Canada Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Technology
      • 7.3.3.2.2.By Sample Type
      • 7.3.3.2.3.By Panel Type
      • 7.3.3.2.4.By End-User

8.South America Lung Cancer Genomic Testing Medicine Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Technology
  • 8.2.2.By Sample Type
  • 8.2.3.By Panel Type
  • 8.2.4.By End-User
  • 8.2.5.By Country
• 8.3.South America: Country Analysis
  • 8.3.1.Brazil Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Technology
      • 8.3.1.2.2.By Sample Type
      • 8.3.1.2.3.By Panel Type
      • 8.3.1.2.4.By End-User
  • 8.3.2.Argentina Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Technology
      • 8.3.2.2.2.By Sample Type
      • 8.3.2.2.3.By Panel Type
      • 8.3.2.2.4.By End-User
  • 8.3.3.Colombia Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Technology
      • 8.3.3.2.2.By Sample Type
      • 8.3.3.2.3.By Panel Type
      • 8.3.3.2.4.By End-User

9.Middle East and Africa Lung Cancer Genomic Testing Medicine Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Technology
  • 9.2.2.By Sample Type
  • 9.2.3.By Panel Type
  • 9.2.4.By End-User
  • 9.2.5.By Country
• 9.3.MEA: Country Analysis
  • 9.3.1.South Africa Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Technology
      • 9.3.1.2.2.By Sample Type
      • 9.3.1.2.3.By Panel Type
      • 9.3.1.2.4.By End-User
  • 9.3.2.Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Technology
      • 9.3.2.2.2.By Sample Type
      • 9.3.2.2.3.By Panel Type
      • 9.3.2.2.4.By End-User
  • 9.3.3.UAE Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Technology
      • 9.3.3.2.2.By Sample Type
      • 9.3.3.2.3.By Panel Type
      • 9.3.3.2.4.By End-User

10.Market Dynamics

• 10.1.Drivers
• 10.2.Challenges

11.Market Trends Developments

• 11.1.Recent Developments
• 11.2.Product Launches
• 11.3.Mergers Acquisitions

12.Global Lung Cancer Genomic Testing Medicine Market: SWOT Analysis

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Product

14.Competitive Landscape

• 14.1.QIAGEN NV
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Product Services
  • 14.1.5.Financials (In case of listed)
  • 14.1.6.Recent Developments
  • 14.1.7.SWOT Analysis
• 14.2.Agilent Technologies Inc.
• 14.3.Thermo Fisher Scientific Inc.
• 14.4.Quest Diagnostics Incorporated
• 14.5.Laboratory Corporation of America Holdings
• 14.6.CENTOGENE N.V.
• 14.7.BGI Genomics Co. Ltd.
• 14.8.CeGaT GmbH
• 14.9.Illumina Inc.
• 14.10.F. Hoffmann-La Roche Ltd

15.Strategic Recommendations

16.About Us Disclaimer